Work

Reduction in the Risk of All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol Compared to Umeclidinium/Vilanterol in IMPACT Including Previously Missing or Censored Vital Status Data

Year: 2019

Type: conference-abstract

DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7344

Authors: D.A. Lipson, G.J. Criner, N. Day, M.T. Dransfield, D.M.G. Halpin, M.K. Han, C.E. Jones, S. Kilbride, P. Lange, D.A. Lomas, P. Manchester, F.J. Martinez, D. Midwinter, A.N. Morris, S.J. Pascoe, D. Singh, R.A. Wise

Institutions: GlaxoSmithKline (United States), University of Pennsylvania, Temple University, GlaxoSmithKline (United Kingdom), University of Alabama at Birmingham, Royal Devon and Exeter Hospital, University of Michigan, University of Copenhagen, Gentofte Hospital, University College London, NewYork–Presbyterian Hospital, Weill Cornell Medical Center, University of Manchester, Johns Hopkins University

Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2970438590

Cites:

Cited by: 5

Related to: 10